Reports

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Vasomotor Symptoms Treatment Market Share, Size, Analysis, Forecast: By Route of Administration: Oral, Parenteral, Topical; By Type of Therapy: Hormonal Therapies, Non-Hormonal Therapies, Others; By Distribution Channel: Hospital Based Pharmacies, Online Pharmacies, Retail Pharmacies; Regional Analysis; Supplier Landscape; 2023-2031

Global Vasomotor Symptoms Treatment Market Outlook

The vasomotor symptoms treatment market size was estimated to be worth USD 8.8 billion in 2022. Driven by the rise in the number of vasomotor symptoms cases, the market is expected to rise at a CAGR of 6.70% during the forecast period of 2023-2031 to attain a value of more than USD 15.7 billion by 2031.

 

Vasomotor Symptoms: Insights, Causes, Risk Factors, and Treatment

Vasomotor symptoms are the symptoms that occur during menopause due to the constriction of blood vessels. The common vasomotor symptoms include hot flashes, night sweats, and changes in blood pressure.

 

Vasomotor symptoms occur at menopause because of the substantial hormonal changes that can affect the blood pressure and temperature regulator of the body. The significant estrogen level decrease triggers the nervous system, making the patient restless.

 

Vasomotor symptoms are more prevalent in African Americans than in Asian Americans. Smoking and obesity further increase the chances of this disorder.

 

The management of vasomotor symptoms is done using medications. The first-line treatment includes the use of hormonal regulators and anti-depressant drugs. Several lifestyle remedies are also incorporated to manage vasomotor symptoms.

 

According to the vasomotor symptoms treatment market research report, the market can be categorised into the following segments:

Market Breakup by Route of Administration

  • Oral
  • Parenteral
    • Intravenous
    • Subcutaneous
  • Topical

 

Market Breakup by Type of Therapy

  • Hormonal Therapies
    • Estrogen Replacement Therapies
    • Pregestational Therapies
  • Non-Hormonal Therapies
    • Clonidine
    • Serotonin Reuptake Inhibitors
    • Gabapentin
  • Others

 

Market Breakup by Distribution Channel

  • Hospital Based Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

 

Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

 

Vasomotor Symptoms Treatment Market Scenario

The rising prevalence of vasomotor symptoms, such as hot flashes and night sweats during menopausal phases, is anticipated to boost the market growth. According to the International Journal of Applied & Basic Medical Research, nearly 88% of women reported menopausal and vasomotor symptoms, thus facilitating the demand for more therapeutic options.

 

The increasing investments in the research and development activities by the key players are driving the treatment of the vasomotor symptoms treatment market development. This further contributes to the discovery of novel therapeutic interventions, that will propel the market expansion.

 

Additional factors, such as a rise in the adoption of a sedentary lifestyle, an increase in the number of mergers and acquisitions, and raising awareness regarding vasomotor symptoms are attributing to the growth of the market.

 

Regional Insights

North America is anticipated to account for the largest revenue share of the global market. This is due to the high incidence of post-menopausal symptoms, raising awareness about women’s health, and increasing expenditure in the healthcare sector. The significant presence of key global players in this region is also projected to boost the market growth.

 

During the forecast period, Latin America is expected to witness the fastest growth in the vasomotor symptoms treatment market. The factors leading to this rapid growth include the rising awareness regarding menopausal symptoms and more significant expenditure in the research and development sector.

 

Therapeutic Landscape

There are several therapeutic interventions for the management of vasomotor symptoms. The procedures used for the treatment of vasomotor symptoms are pharmacological and non-pharmacological. In pharmacological ones, there are two main primary therapies, hormonal replacement therapy (HRT) and non-hormonal medications.

 

Standard Therapies: Hormonal and Non-Hormonal Therapeutic Interventions

During menopause, there is a substantial reduction in the levels of oestrogen and progesterone. Hormonal replacement therapies are generally utilised to restore reduced hormonal levels, which will subsequently help regulate average body temperature. There are two hormone replacement therapies, oestrogen therapy and oestrogen progesterone hormone therapy.

 

Hormonal replacement therapies have associated adverse effects; therefore, there is a shift toward non-hormonal medications. Different medications can be incorporated into the treatment regimen depending on the vasomotor symptoms. Serotonin reuptake inhibitors, such as citalopram and fluoxetine, are generally used for hot flashes.

 

Other medications, such as antidepressants, anti-seizure, urinary, blood pressure, and over-the-counter drugs, also help alleviate vasomotor symptoms.

 

Alternative treatments, including acupuncture, hypnosis, meditation, and relaxation techniques, have been beneficial for managing menopausal and vasomotor symptoms.

 

Clinical Trial Landscape

The currently available therapies are associated with several adverse effects and thus leading to several other diseases and comorbidities. Hence, scientists are performing clinical trials for novel therapeutic interventions that will be more effective and have fewer side effects.

 

Emerging Therapies: Discovery of Novel Medications

M2S Hot Flash Study, an ongoing clinical trial by Fervent Pharmaceuticals, is being performed to manage vasomotor symptoms. This virtual Phase II clinical trial treats moderate night sweats and hot flashes. The primary objective is to analyse the safety and efficacy of peri and post-menopausal therapy.

 

Astellas Pharma, a key player, is performing a SKYLIGHT 4 clinical trial study to assess the safety and efficacy of fezolinetant, a non-hormonal therapy. Phase III trials are under process for testing the safety and tolerability of this investigational selective neurokinin three receptor antagonist on endometrial health.

 

Another set of clinical trials is undergoing for the novel neurokinin three receptor antagonist, which is anticipated to provide the potential treatment for managing vasomotor symptoms. Acer Therapeutics is conducting Phase II clinical trials for its ACER-801 (osanetant) drug, and if successfully approved can benefit in the alleviation of vasomotor symptoms.

 

With the increasing number of key players, there is a rise in the number of drugs under the pipeline. These novel products' approval and launch are expected to boost the market growth.

 

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the vasomotor symptoms treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

 

  • Bayer AG
  • Fervent Pharmaceuticals, LLC
  • Astellas Pharma Inc.
  • Frazier Healthcare Partners
  • Mitsubishi Tanabe Pharma Corporation
  • Eli Lilly and Company
  • AbbVie Inc.
  • AMAG Pharmaceuticals Inc.
  • Emcure Pharmaceuticals Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2022
Historical Period 2016-2022
Forecast Period 2023-2031
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Route of Administration
  • Type of Therapy
  • Distribution Channel
  • Region
Breakup by Route of Administration
  • Oral
  • Parenteral
  • Topical
Breakup by Type of Therapy
  • Hormonal Therapies
  • Non-Hormonal Therapies
  • Others
Breakup by Distribution Channel
  • Hospital Based Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Bayer AG
  • Fervent Pharmaceuticals, LLC
  • Astellas Pharma Inc.
  • Frazier Healthcare Partners
  • Mitsubishi Tanabe Pharma Corporation
  • Eli Lilly and Company
  • AbbVie Inc.
  • AMAG Pharmaceuticals Inc.
  • Emcure Pharmaceuticals Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
        1.1.1    Research Objectives
        1.1.2    Key Findings of the Report
    1.2    Limitations of the Study and Scope for Future Research
2    Research Methodology
3    Executive Summary
4    Global Vasomotor Symptoms Overview

    4.1    Guidelines and Stages
    4.2    Pathophysiology
    4.3    Screening and Diagnosis
    4.4    Treatment Pathway 
5    Patient Profile
    5.1    Patient Profile Overview
    5.2    Patient Psychology and Emotional Impact Factors
    5.3    Risk Assessment and Treatment Success Rate
6    Global Vasomotor Symptoms Treatment Market 
    6.1    Global Vasomotor Symptoms Treatment Market Overview
    6.2    Global Vasomotor Symptoms Treatment Market Analysis 
        6.2.1    Market  Overview
            6.2.1.1    Global Vasomotor Symptoms Treatment Market Historical Value (2016-2022) 
            6.2.1.2    Global Vasomotor Symptoms Treatment Market Forecast Value (2023-2031)
    6.3    Global Vasomotor Symptoms Treatment Market by Route of Administration 
        6.3.1    Market Overview
            6.3.1.1    Oral
            6.3.1.2    Parenteral
                6.3.1.2.1    Subcutaneous
                6.3.1.2.2    Intravenous
            6.3.1.3    Topical
    6.4    Global Vasomotor Symptoms Treatment Market by Type of Therapy
        6.4.1    Market Overview
            6.4.1.1    Hormonal Therapies
                6.4.1.1.1    Estrogen Replacement Therapies
                6.4.1.1.2    Pregestational Therapies
            6.4.1.2    Non-Hormonal Therapies
                6.4.1.2.1    Clonidine
                6.4.1.2.2    Serotonin Reuptake Inhibitors
                6.4.1.2.3    Gabapentin
            6.4.1.3    Others
    6.5    Global Vasomotor Symptoms Treatment Market by Distribution Channel
        6.5.1    Market Overview
            6.5.1.1    Hospital Based Pharmacies
            6.5.1.2    Online Pharmacies
            6.5.1.3    Retail Pharmacies
    6.6    Global Vasomotor Symptoms Treatment Market by Region
        6.6.1    Market Overview
            6.6.1.1    North America 
                6.6.1.1.1    Historical Trend (2016-2022)
                6.6.1.1.2    Forecast Trend (2023-2031)
            6.6.1.2    Europe
                6.6.1.2.1    Historical Trend (2016-2022)
                6.6.1.2.2    Forecast Trend (2023-2031)
            6.6.1.3    Asia Pacific
                6.6.1.3.1    Historical Trend (2016-2022)
                6.6.1.3.2    Forecast Trend (2023-2031)
            6.6.1.4    Latin America
                6.6.1.4.1    Historical Trend (2016-2022)
                6.6.1.4.2    Forecast Trend (2023-2031)
            6.6.1.5    Middle East and Africa
                6.6.1.5.1     Historical Trend (2016-2022)
                6.6.1.5.2    Forecast Trend (2023-2031)
7    North America Vasomotor Symptoms Treatment Market
    7.1    United States of America
        7.1.1    Historical Trend (2016-2022)
        7.1.2    Forecast Trend (2023-2031)
    7.2    Canada 
        7.2.1    Historical Trend (2016-2022)
        7.2.2    Forecast Trend (2023-2031)
8    Europe Vasomotor Symptoms Treatment Market
    8.1    United Kingdom
        8.1.1    Historical Trend (2016-2022)
        8.1.2    Forecast Trend (2023-2031)
    8.2    Germany
        8.2.1    Historical Trend (2016-2022)
        8.2.2    Forecast Trend (2023-2031)
    8.3    France
        8.3.1    Historical Trend (2016-2022)
        8.3.2    Forecast Trend (2023-2031)
    8.4    Italy
        8.4.1    Historical Trend (2016-2022)
        8.4.2    Forecast Trend (2023-2031)
9    Asia Pacific Vasomotor Symptoms Treatment Market
    9.1    China
        9.1.1    Historical Trend (2016-2022)
        9.1.2    Forecast Trend (2023-2031)
    9.2    Japan
        9.2.1    Historical Trend (2016-2022)
        9.2.2    Forecast Trend (2023-2031)
    9.3    India
        9.3.1    Historical Trend (2016-2022)
        9.3.2    Forecast Trend (2023-2031)
    9.4    ASEAN
        9.4.1    Historical Trend (2016-2022)
        9.4.2    Forecast Trend (2023-2031)
    9.5    Australia
        9.5.1    Historical Trend (2016-2022)
        9.5.2    Forecast Trend (2023-2031)
10    Latin America Vasomotor Symptoms Treatment Market
    10.1    Brazil
        10.1.1    Historical Trend (2016-2022)
        10.1.2    Forecast Trend (2023-2031)
    10.2    Argentina
        10.2.1    Historical Trend (2016-2022)
        10.2.2    Forecast Trend (2023-2031)
    10.3    Mexico
        10.3.1    Historical Trend (2016-2022)
        10.3.2    Forecast Trend (2023-2031)
11    Middle East and Africa Vasomotor Symptoms Treatment Market
    11.1    Saudi Arabia
        11.1.1    Historical Trend (2016-2022)
        11.1.2    Forecast Trend (2023-2031)
    11.2    United Arab Emirates
        11.2.1    Historical Trend (2016-2022)
        11.2.2    Forecast Trend (2023-2031)
    11.3    Nigeria
        11.3.1    Historical Trend (2016-2022)
        11.3.2    Forecast Trend (2023-2031)
    11.4    South Africa
        11.4.1    Historical Trend (2016-2022)
        11.4.2    Forecast Trend (2023-2031)
12    Current Scenario Evaluation and Regulatory Framework
    12.1    Emerging Therapies and Clinical Trials
    12.2    Patent Landscape 
        12.2.1    Patent Overview
            12.2.1.1    Patent Status and Expiry
            12.2.1.2    Timelines from Drug Development to Commercial Launch
            12.2.1.3    New Drug Application
                12.2.1.3.1    Documentation and Approval Process
    12.3    Cost of Treatment
    12.4    Regulatory Framework
        12.4.1    Regulatory Overview
            12.4.1.1    US FDA
            12.4.1.2    EU EMA
            12.4.1.3    INDIA CDSCO
            12.4.1.4    JAPAN PMDA
            12.4.1.5    Others
13    Challenges and Unmet Needs
    13.1    Treatment Pathway Challenges
    13.2    Compliance and Drop-Out Analysis
    13.3    Awareness and Prevention Gaps
14    Global Vasomotor Symptoms Treatment Market Dynamics
    14.1    Market Drivers and Constraints
    14.2    SWOT Analysis
    14.3    Porter’s Five Forces Model
    14.4    Key Demand Indicators 
    14.5    Key Price Indicators 
    14.6    Industry Events, Initiatives and Trends
    14.7    Value Chain Analysis
15    Supplier Landscape
    15.1    Bayer AG 
        15.1.1    Company Overview
        15.1.2    Product Portfolio
        15.1.3    Demographic Reach and Achievements
        15.1.4    Mergers and Acquisitions
        15.1.5    Certifications
    15.2     Fervent Pharmaceuticals, LLC
        15.2.1    Company Overview
        15.2.2    Product Portfolio
        15.2.3    Demographic Reach and Achievements
        15.2.4    Mergers and Acquisitions
        15.2.5     Certifications
    15.3     Astellas Pharma Inc.
        15.3.1    Company Overview
        15.3.2    Product Portfolio
        15.3.3    Demographic Reach and Achievements
        15.3.4    Mergers and Acquisitions
        15.3.5    Certifications
    15.4    Frazier Healthcare Partners
        15.4.1    Company Overview
        15.4.2    Product Portfolio
        15.4.3    Demographic Reach and Achievements
        15.4.4    Mergers and Acquisitions
        15.4.5    Certifications
    15.5    Mitsubishi Tanabe Pharma Corporation
        15.5.1    Company Overview
        15.5.2    Product Portfolio
        15.5.3    Demographic Reach and Achievements
        15.5.4    Mergers and Acquisitions
        15.5.5    Certifications
    15.6    Eli Lilly and Company
        15.6.1    Company Overview
        15.6.2    Product Portfolio
        15.6.3    Demographic Reach and Achievements
        15.6.4    Mergers and Acquisitions
        15.6.5    Certifications
    15.7    AbbVie Inc.
        15.7.1    Company Overview
        15.7.2    Product Portfolio
        15.7.3    Demographic Reach and Achievements
        15.7.4    Mergers and Acquisitions
        15.7.5    Certifications
    15.8    AMAG Pharmaceuticals Inc.
        15.8.1    Company Overview
        15.8.2    Product Portfolio
        15.8.3    Demographic Reach and Achievements
        15.8.4    Mergers and Acquisitions
        15.8.5    Certifications
    15.9    Emcure Pharmaceuticals Limited
        15.9.1    Company Overview
        15.9.2    Product Portfolio
        15.9.3    Demographic Reach and Achievements
        15.9.4    Mergers and Acquisitions
        15.9.5    Certifications 
    15.10    Merck & Co., Inc. 
        15.10.1    Company Overview
        15.10.2    Product Portfolio
        15.10.3    Demographic Reach and Achievements
        15.10.4    Mergers and Acquisitions
        15.10.5    Certifications
    15.11    Novartis AG 
        15.11.1    Company Overview
        15.11.2    Product Portfolio
        15.11.3    Demographic Reach and Achievements
        15.11.4    Mergers and Acquisitions
        15.11.5    Certifications
    15.12    Novo Nordisk A/S 
        15.12.1    Company Overview
        15.12.2    Product Portfolio
        15.12.3    Demographic Reach and Achievements
        15.12.4    Mergers and Acquisitions
        15.12.5    Certifications
    15.13    Pfizer Inc. 
        15.13.1    Company Overview
        15.13.2    Product Portfolio
        15.13.3    Demographic Reach and Achievements
        15.13.4    Mergers and Acquisitions
        15.13.5    Certifications
    15.14    Teva Pharmaceutical Industries Ltd.
        15.14.1    Company Overview
        15.14.2    Product Portfolio
        15.14.3    Demographic Reach and Achievements
        15.14.4    Mergers and Acquisitions
        15.14.5    Certifications 
16    Recommendations and Discussion
17    Global Vasomotor Symptoms Treatment Drugs Distribution Model (Additional Insight)

    17.1    Overview 
    17.2    Potential Distributors
    17.3    Key Parameters for Distribution Partner Assessment 
18    Payment Methods (Additional Insight)
    18.1    Government Funded
    18.2    Private Insurance
    18.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of USD 8.8 billion in 2022, driven by the rising prevalence of the disease.

The market is likely to grow at a CAGR of 6.7% during the forecast period of 2023-2031 to attain a value of USD 15.7 billion by 2031.

The increasing prevalence of vasomotor symptoms, evolving healthcare infrastructure, and more significant investments in the research and development sector are primarily driving the market growth.

Based on the route of administration, the market can be segmented into oral, parenteral, and topical.

Based on the therapy type, the market is divided into hormonal and non-hormonal therapies, among others.

Based on the distribution channel, the market can be categorised into hospital pharmacies, online pharmacies, and retail pharmacies.

On a regional level, the market has been categorised into North America, Latin America, Europe, Asia Pacific, and Middle East and Africa. North America is anticipated to hold the maximum share in the market.

The key companies involved in the market are Bayer AG, Fervent Pharmaceuticals, LLC, Astellas Pharma Inc., Frazier Healthcare Partners, Mitsubishi Tanabe Pharma Corporation, Eli Lilly and Company, AbbVie Inc., AMAG Pharmaceuticals Inc., Emcure Pharmaceuticals Limited, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., and Teva Pharmaceutical Industries Ltd., among others.

Purchase Full Report

Mini Report

$2499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$6499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$7999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER